Revance risk not heightened from FDA guidance, says Piper Jaffray Piper Jaffray does not see heightened risk around Revance's RT001 after the FDA issued draft guidance on clinical endpoints for botulinum toxin products for the treatment of upper facial lines. The firm reiterates an Overweight rating on the stock with a $44 price target.
Revance initiates dosing in Phase 2 study of RT002 for cervical dystonia Revance Therapeutics announced the initiation of patient dosing in a Phase 2 dose-escalating clinical study of RT002 investigational drug product candidate to treat cervical dystonia. The study will evaluate safety, preliminary efficacy, and duration of effect of a single treatment of RT002 for injection in patients with moderate-to-severe isolated cervical dystonia symptoms of the neck. The company plans to release interim results in 2016. Approximately 36 patients with at least moderate cervical dystonia are expected to be enrolled at multiple sites in the United States. There will be three treatment groups of approximately 12 patients each who will be treated with one of three doses of RT002 for injection.